Literature DB >> 16170340

Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5.

J M Angelastro1, P D Canoll, J Kuo, M Weicker, A Costa, J N Bruce, L A Greene.   

Abstract

Glioblastoma multifome is the most common and most aggressive primary brain tumor with no current curative therapy. We found expression of the bZip transcription factor ATF5 in all 29 human glioblastomas and eight human and rat glioma cell lines assessed. ATF5 is not detectably expressed by mature brain neurons and astrocytes, but is expressed by reactive astrocytes. Interference with ATF5 function or expression in all glioma cell lines tested causes marked apoptotic cell death. In contrast, such manipulations do not affect survival of ATF5-expressing cultured astrocytes or of several other cell types that express this protein. In a proof-of-principle experiment, retroviral delivery of a function-blocking mutant form of ATF5 into a rat glioma model evokes death of the infected tumor cells, but not of infected brain cells outside the tumors. The widespread expression of ATF5 in glioblastomas and the selective effect of interference with ATF5 function/expression on their survival suggest that ATF5 may be an attractive target for therapeutic intervention in such tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16170340     DOI: 10.1038/sj.onc.1209116

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

1.  BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner.

Authors:  Douglas Dluzen; Guangfu Li; Diana Tacelosky; Matthew Moreau; David X Liu
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

Review 2.  Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR.

Authors:  Pan Deng; Cole M Haynes
Journal:  Semin Cancer Biol       Date:  2017-05-10       Impact factor: 15.707

3.  miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma.

Authors:  Mengyuan Wang; Ming Hu; Zhaohua Li; Dongmeng Qian; Bin Wang; David X Liu
Journal:  Biochem Biophys Res Commun       Date:  2017-06-07       Impact factor: 3.575

4.  Expression and targeting of transcription factor ATF5 in dog gliomas.

Authors:  D York; C D Sproul; N Chikere; P J Dickinson; J M Angelastro
Journal:  Vet Comp Oncol       Date:  2017-05-08       Impact factor: 2.613

5.  Influence of the valine zipper region on the structure and aggregation of the basic leucine zipper (bZIP) domain of activating transcription factor 5 (ATF5).

Authors:  Natalie A Ciaccio; T Steele Reynolds; C Russell Middaugh; Jennifer S Laurence
Journal:  Mol Pharm       Date:  2012-10-23       Impact factor: 4.939

6.  A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.

Authors:  Zhi Sheng; Li Li; Lihua J Zhu; Thomas W Smith; Andrea Demers; Alonzo H Ross; Richard P Moser; Michael R Green
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

Review 7.  The transcription factor ATF5: role in neurodevelopment and neural tumors.

Authors:  Lloyd A Greene; Hae Young Lee; James M Angelastro
Journal:  J Neurochem       Date:  2008-11-15       Impact factor: 5.372

Review 8.  Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system.

Authors:  Huining He; Allan David; Beata Chertok; Adam Cole; Kyuri Lee; Jian Zhang; Jianxin Wang; Yongzhuo Huang; Victor C Yang
Journal:  Pharm Res       Date:  2013-01-24       Impact factor: 4.200

9.  Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients.

Authors:  Jason A Ellis; Allen Waziri; Casilda Balmaceda; Peter Canoll; Jeffrey N Bruce; Michael B Sisti
Journal:  J Neurooncol       Date:  2009-06-17       Impact factor: 4.130

10.  Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells.

Authors:  Guangfu Li; Wenhong Li; James M Angelastro; Lloyd A Greene; David X Liu
Journal:  Mol Cancer Res       Date:  2009-06-16       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.